Financial Performance Q1FY27
- Revenue from Operations: Increased 29% YoY
- EBITDA: ₹9.211 Cr, grew 17% YoY from ₹7.879 Cr
- EBITDA Margin: 41% (vs 45% in Q1FY26)
- Profit After Tax: ₹6.569 Cr, grew 28% YoY from ₹5.131 Cr
- PAT Margin: 28% (vs 29% in Q1FY26)
- Basic EPS: ₹5.28 (vs ₹4.13 in Q1FY26)
- Gross Profit Margin: 89% (11 bps improvement YoY)
- Operating Expenses: ₹10.662 Cr (38% increase YoY)
- Finance Cost: ₹0.347 Cr (109% increase YoY)
- Other Income: ₹1.402 Cr (1212% increase YoY)
Business Segment Performance
- Ayurveda Healthcare Products Business: 47% YoY growth in Q1FY27
- Panchkarma Revenue: 13% YoY growth in Q1FY27
- IPD Patients: 33% YoY increase in Q1FY27
- Day Care Volumes: 31% YoY growth to 19,419 patients per day
Operational Metrics
- Total Beds: 3,031 (2,400 operational, 450 in pipeline)
- Operational Clinics & Day Care Centers: 57
- Cities & Towns Covered: 100+
- States Covered: 23
- Ayurveda Medicine & Product Portfolio: 330+ SKUs
- NABH Accredited Hospitals & Clinics: 51 (with 2 additional in pipeline)
- Doctors & Medical Staff: 959 total (601 certified Ayurveda doctors)
- Franchisee Operated Centers: 31
Expansion and Development
- First ultra-luxury wellness resort signed in Manali, Himachal Pradesh with 108 rooms, 22 upcoming villas, and planned helipad
- 5 facilities in pipeline
- Continued network expansion to increase treatment capacity
Sales and Marketing
- Social Media Followers: 16M+ across channels (YouTube: 2,847,890; Facebook: 8,797,000; Instagram: 4,302,700)
- Health Camps: 4 camps organized in Q1FY27 with 309 cumulative visitors
- Average ~30% conversion of camp attendees for IPD treatments
- Client Support Centre for proactive customer engagement
Insurance and Government Empanelment
- Empanelled with CGHS, CAPF, ECHS
- State government panels: Uttar Pradesh, Bihar, Haryana, Punjab
- Additional empanelments: DDA, CBSE, CSIR, DERC, DHC, BIS, Narmada Control Authority, TRAI, CERC, NHAI, MMTC, IWAI, DFCCIL, Air India, GAIL, GYPSA, MPPGCL, Navodaya, Maruti Suzuki Limited
- Private insurance company empanelments
Product Portfolio
- Top Selling Products: Dr. BP Care DS, Dr. Kidney Care DS, Dr. Madhu Care DS, Dr. Liver DS, Dr. Sukoon DS
- INJK Water Device: Launched December 2024, became largest contributor to portfolio in Q1FY27
- Upcoming Products: Plant Based Protein Powder, Gyno Syrup, Joint Pain Oil, Joint Pain Ointment, Joint Pain Balm, Joint Pain Tablets
- All products compliant with AYUSH Standards
Management and Governance
- Managing Director: Manish Grover
- Board includes independent directors and executive directors
- Forvis Mazars appointed as new Internal Auditor
- Consistent dividend payout in FY23, FY24, FY25
- Migrated to NSE & BSE mainboard in August 2025
Market Data (as of August 7, 2026)
- Current Market Price: ₹598.1
- 52 Week High/Low: ₹849.5/₹492.0
- Shares Outstanding: 12.43 Cr
- Market Capitalization: ₹7,470.47 Cr
- FII+DII Holding: 5.14% (as of June 30, 2026)
- Industry Classification: Healthcare
- NSE Listing Date: April 19, 2022
- BSE Listing Date: August 11, 2025
Historical Financial Performance (FY22-FY26)
- Revenue Growth: FY22: ₹14,645 Lakhs, FY26: ₹80,135 Lakhs
- EBITDA Margin: Improved from 12% (FY22) to 44% (FY26)
- PAT Margin: Improved from 8% (FY22) to 27% (FY26)
- 3Y Top Line CAGR: One of the fastest growing healthcare enterprises
Additional Information
Presentation available on company website: www.jeenasikho.com
Investor Relations contact: Go India Advisors (Soumya Chhajed, Shrutee Barve)
Company Address: SCO 11, First Floor, Kalgidhar enclave, Kalka Shimla Highway, Near K-Area Road, Baltana Light Point, Zirakpur, Chandigarh District Mohali, Punjab - 140604